FLOXIN OTIC Rx
Generic Name and Formulations:
Ofloxacin 0.3%; otic soln.
Indications for FLOXIN OTIC:
Otitis externa in adults and children. Chronic suppurative otitis media in adults with perforated tympanic membrane. Acute otitis media in children with tympanostomy tubes.
Adults and Children:
<6months: not recommended. Otitis externa: 6months–13yrs: 5 drops in affected ear(s) once daily. ≥13yrs: 10 drops in affected ear(s) once daily. Both: treat for 7 days. Acute otitis media: 1–12yrs: 5 drops in affected ear(s) twice daily for 10 days. Chronic suppurative otitis media: ≥12yrs: 10 drops in affected ear(s) twice daily for 14 days.
Discontinue if hypersensitivity reaction occurs. Reevaluate if no improvement after 1 week. Pregnancy (Cat.C). Nursing mothers: not recommended.
Pruritus, taste perversion, local reactions, dizziness, earache, headache, vertigo, superinfection, paresthesia, rash.
Soln—5mL, 10mL (dropper bottles); Singles 0.25mL (5 drops/container)—20
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|